All News

A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.

Alembic Pharmaceuticals has received FDA approval for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%, therapeutically equivalent to Trusopt Ophthalmic Solution, 2% (Merck Sharp & Dohme Corp.).

Top news of the day from across the health care landscape.

Genomind is expanding its mental health genetic testing services with the addition of Genomind Professional PGx Express, which provides a more focused report and set of services to enhance the preexisting mental health genetic test.

The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.

Investigators believe that urine sampling can be used to diagnose and treat bladder cancer.

Top news of the day from across the health care landscape.

In an ideal world, how would you hypothesize that technology might be able to solve all of your problems?

What is causing the suspicious MRI results?

An FDA committee has recommended approval of Gilead’s Descovy to reduce the risk of sexually acquired HIV infection in those at high risk of acquiring the virus.

An FDA committee voted 16 to 2 to recommended emitricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for a HIV pre-exposure prophylaxis indication.

These new Guarded Luer Connectors are used to join two luer lock syringes or other luer lock devices.

As new pharmacists receive their exam results and enter the workforce, many are facing questions about their school experiences, career plans, further education plans, and the rising debt students face.

Galcanezumab-gnlm (Emgality, Eli Lilly) may be an effective option for patients who failed previous migraine preventive treatments.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), named public health expert and former commissioner of the Food and Drug Administration (FDA) Scott Gottlieb, M.D., as the keynote speaker for the 37th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.®

The phase 3 IMvigor130 study is the first to assess a cancer immunotherapy combination in previously untreated advanced bladder cancer.

High school students will explore pharmacy careers through activities such as extracting DNA from strawberries, and getting out of a pharmacy-themed escape room, during the upcoming Discover Pharmacy day camp, at Wilkes University.

By searching for hyperactive cell signals in primary effusion lymphoma, researchers were able to find a pathway that can be blocked to limit tumor growth.

Top news of the day from across the health care landscape.

Vizient, Inc. has released its July 2019 Drug Price Forecast, which projects that health systems can expect a 4.57% increase for pharmaceutical purchases made in 2020.

Pharmacy and public health associations have released statements following the recent shootings in California, Texas, and Ohio, and some are discussing what actions they can take to prevent further gun-related injury and death.

The conference will take place in conjunction with the 7th National Association of Specialty Pharmacy Annual Meeting & Expo.

Drug overdoses involving opioids have increased, and naloxone can be a life-saving drug to prevent deaths.

A study in the Bukoba municipality of Tanzania has suggested that scaling up HIV testing, improving linkages to HIV care, and strengthening retention of antiretroviral therapy interventions can help increase viral load suppression (VLS).

A regimen of afatinib as a first-line treatment followed by osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer was found to significantly improve overall survival.

Identifying gene-pair relationships may help scientists understand why mutations in certain genes lead to cancer in certain tissues.

Top news of the day from across the health care landscape.

Officials with the FDA issued a statement to clarify data accuracy issues with recently-approved gene therapy Zolgensma (onasemnogene abeparvovec-xioi, AveXis), a product intended to treat spinal muscular atrophy (SMA) in children under 2 years old.